TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $1,323,247.50 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

TransMedics Group Trading Up 3.2 %

NASDAQ:TMDX traded up $4.87 on Tuesday, reaching $156.08. The company’s stock had a trading volume of 821,976 shares, compared to its average volume of 773,351. The firm has a market cap of $5.21 billion, a PE ratio of -459.06 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The business’s 50-day moving average price is $154.40 and its two-hundred day moving average price is $127.98. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. During the same period last year, the company posted ($0.03) EPS. The business’s quarterly revenue was up 117.7% on a year-over-year basis. Equities research analysts anticipate that TransMedics Group, Inc. will post 1.23 earnings per share for the current fiscal year.

Institutional Trading of TransMedics Group

Several hedge funds and other institutional investors have recently modified their holdings of the company. Fidelis Capital Partners LLC acquired a new position in shares of TransMedics Group during the first quarter worth about $35,000. International Assets Investment Management LLC bought a new position in shares of TransMedics Group during the 2nd quarter worth approximately $47,000. J.Safra Asset Management Corp raised its holdings in shares of TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the last quarter. Signaturefd LLC lifted its position in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Amalgamated Bank grew its position in TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TMDX shares. Canaccord Genuity Group increased their target price on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald initiated coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price for the company. Morgan Stanley upped their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Needham & Company LLC initiated coverage on shares of TransMedics Group in a research report on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price objective for the company. Finally, Stephens increased their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.44.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.